EGM
MRKR icon

Engineers Gate Manager’s Marker Therapeutics MRKR Stock Holding History

Engineers Gate Manager’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,442
Closed -$51.1K – 2428
2024
Q4 		$51.1K Buy
+16,442
New +$58.2K ﹤0.01% 2083
2022
Q1 		– Sell
-1,194
Closed -$11K – 2146
2021
Q4 		$11K Buy
+1,194
New +$15.9K ﹤0.01% 1957

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Engineers Gate Manager's MRKR Position: Q1 2025 in Review

Engineers Gate Manager sold out of Marker Therapeutics (MRKR) in Q1 2025, closing a stake of 16,442 shares — an estimated $51.1K sold.

Engineers Gate Manager first reported a position in MRKR in Q4 2021 and held it in 2 quarters. The position peaked at $51.1K in Q4 2024. 32 funds tracked by Wall St. Rank hold MRKR as of Q1 2025.

  • Engineers Gate Manager reported no remaining Marker Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Engineers Gate Manager sold 16,442 Marker Therapeutics shares in Q1 2025, an estimated $51.1K.
  • Engineers Gate Manager first reported a position in Marker Therapeutics in Q4 2021 and held it in 2 quarters.
  • Engineers Gate Manager's Marker Therapeutics position peaked at $51.1K in Q4 2024.
  • 32 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2025.

Based on Engineers Gate Manager's 13F filing for Q1 2025, filed 15 May 2025.